September 10, 2008 - EDAP TMS SA, a therapeutic ultrasound developer, will launch initial HIFU services, a noninvasive prostate cancer treatment that uses high-intensity focused ultrasound, at Amphia Ziekenhis Hospital, in Breda, the first Ablatherm robotic HIFU treatment center in the Netherlands.
Dr. Harald Janssen, head of the urology department at Amphia Ziekenhis Hospital, in Breda, Netherlands, commented, “The Ablatherm device will enable our center to be at the forefront of the treatment of prostate cancer with the latest technologies. I have been impressed with the technology and the minimally invasive approach of the Ablatherm-HIFU system. Our first patients were successfully treated with no complications, following a comprehensive training program under EDAP’s leadership. We have additional patients scheduled for treatment and I look forward to expanding the number of treatment volumes at Amphia Ziekenhis to those patients suffering from localized prostate cancer.”
The company expects to add two new centers in the Netherlands that will use Ablatherm-HIFU treatment on a mobile RPP basis.